When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
about
Prevention of HIV-1 infection with early antiretroviral therapyPurinergic Receptors: Key Mediators of HIV-1 Infection and InflammationAn Illustration of Inverse Probability Weighting to Estimate Policy-Relevant Causal EffectsAge at Entry Into Care, Timing of Antiretroviral Therapy Initiation, and 10-Year Mortality Among HIV-Seropositive Adults in the United StatesModeling of HIV-1 infection: insights to the role of monocytes/macrophages, latently infected T4 cells, and HAART regimesRisk factors for delayed entrance into care after diagnosis among patients with late-stage HIV disease in southern VietnamMeasurement Error and Environmental Epidemiology: A Policy PerspectiveEnding the pandemic: reducing new HIV infections to zeroCan we trust the guidelines? Comparison between the data presented and the recommendations of the International Antiviral Society-USA PanelLaboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapyScaling up antiretroviral treatment and improving patient retention in care: lessons from Ethiopia, 2005-2013.Impact of geographic and transportation-related barriers on HIV outcomes in sub-Saharan Africa: a systematic review.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Effects of high CD4 cell counts on death and attrition among HIV patients receiving antiretroviral treatment: an observational cohort studyHIV stigma among substance abusing people living with HIV/AIDS: implications for HIV treatment.Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trialUsing CD4 percentage and age to optimize pediatric antiretroviral therapy initiationEstablishing HIV treatment as prevention in the HIV Prevention Trials Network 052 randomized trial: an ethical odysseyEvolution of HIV treatment guidelines in high- and low-income countries: converging recommendationsEvaluation of the duplication of staging CT scans for localized colon cancer in a Medicare population.Attrition through multiple stages of pre-treatment and ART HIV care in South AfricaAntiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here?Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis.A multicenter study of initiation of antiretroviral therapy and transmitted drug resistance in antiretroviral-naive adolescents and young adults with HIV in New York CityInitiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI StudyA novel Acute Retroviral Syndrome Severity Score predicts the key surrogate markers for HIV-1 disease progression.Changing mortality profile among HIV-infected patients in Rio de Janeiro, Brazil: shifting from AIDS to non-AIDS related conditions in the HAART era.Missed opportunities for HIV testing in newly-HIV-diagnosed patients, a cross sectional study.When to start antiretroviral therapy: the need for an evidence base during early HIV infectionIs clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.Antiretroviral therapy: when to startImmediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up studyGuidelines for antiretroviral therapy in HIV-1 infected adults and adolescents 2014, Thailand.Clinician Perspectives on Delaying Initiation of Antiretroviral Therapy for Clinically Eligible HIV-Infected Patients.HIV infection, immunodeficiency, viral replication, and the risk of cancer.Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort studyPartner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study.
P2860
Q24634688-492D2ACA-5636-4FF2-8AEA-ADCF7A86EDD1Q26774666-FEF48270-A0DB-49C5-860C-4466F22C3A5BQ28386534-ECD8C784-01E0-4A28-857A-5810CA50665CQ28387887-79885735-B84E-473E-BD93-0CD1DF4EE9EDQ28484046-8CD81FD4-E0A1-4A39-9FA8-AB6650E0FF58Q28543860-8C39CECD-5B3C-4316-ACDC-2F478263DF48Q29248055-7233B5F0-C45F-4043-8A45-708BEB2957F0Q30356525-B08E9514-CD6A-4C6A-839A-D54D655F4B31Q30869836-4A642E66-96A1-4B95-8CD5-9519AC60BC85Q33654668-FD4A7260-0B87-4C38-943C-4B42361F1C50Q33714596-DB3FED8B-011D-417C-9F53-23E58DFBE01DQ33717359-8510C2A6-EF8D-4D0E-83E2-D97DA61AA2E2Q33775397-85C8EF4B-6857-4670-B7BA-4B23267F5F4AQ33784615-6FA0602E-6CEC-4312-8AB6-46D103ABDF26Q33980748-E95A1355-673A-44E6-B304-2C8F9EAED88FQ34086963-52037EDC-C4F2-41E6-A232-68A1CDB55449Q34263117-8D7955F8-C80E-4FC0-AAF8-41BD3FBFD48EQ34280961-0586CDF4-9905-411A-88F1-984FCA601B59Q34321843-0A7A4896-034B-482D-8E71-9724035F2C7FQ34339066-F990B2D0-DA9E-4CAA-B3C3-1B61C95536F2Q34374074-45475789-C610-4E56-8C41-F65AA3A38F9AQ34379806-7F9E12C4-6213-4E80-85CC-21EDEB606F9FQ34387168-3F5969B2-ED23-4D14-BC12-5F7EBB2ED223Q34398159-47BB9959-F918-417B-88C2-A353186B2C89Q34485916-6194D497-D885-440A-8C39-57B2EB2A7EC5Q34629153-4A54BD0C-FD71-4EF6-9947-36BF257D1D87Q34662516-267B7E38-71EC-4147-B100-24C425E48400Q34663606-E2095F36-ED3A-468A-8F24-23E0635DB207Q34702924-850950BE-2517-45B3-A87E-944D52EF5584Q34773308-0344FE60-DDE0-4DBA-B6BE-B018A88EA5D4Q34926786-84F5D85C-95EC-455D-9ED0-ABCA874216BFQ35124919-126A18C9-FA87-42C0-BCB4-A10837538BF8Q35142189-B70ED2E1-AF66-450C-93C4-62FCC379144CQ35204279-1C840F8F-7639-478C-9802-D391D9E3815EQ35470434-929FFA34-0D8A-450C-824C-CE2B061AC0A3Q35530299-BEBE1250-65C8-428E-8A1D-B98D8C706442Q35589224-36FC2EDF-6019-409A-A151-9C583D32F4A1Q35612742-4A311529-CEB6-490F-9AC7-5DD3E0AD110AQ35794099-AE53584B-DD21-4EAE-A831-A9AB79704443Q35837001-39BB26F1-F865-42AE-BD2B-1526D7D5BCF8
P2860
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
When to initiate combined anti ...... tries: an observational study.
@ast
When to initiate combined anti ...... tries: an observational study.
@en
type
label
When to initiate combined anti ...... tries: an observational study.
@ast
When to initiate combined anti ...... tries: an observational study.
@en
prefLabel
When to initiate combined anti ...... tries: an observational study.
@ast
When to initiate combined anti ...... tries: an observational study.
@en
P2093
P2860
P50
P1476
When to initiate combined anti ...... tries: an observational study.
@en
P2093
Amy Justice
Anna Esteve
Emilie Lanoy
Frank de Wolf
HIV-CAUSAL Collaboration
Heiner C Bucher
James M Robins
Jonathan A C Sterne
Jordi Casabona
Joseph Goulet
P2860
P304
P356
10.7326/0003-4819-154-8-201104190-00001
P407
P577
2011-04-01T00:00:00Z